LCTX Valuation

Lineage Cell Therapeutics Inc

Add to Watchlist

Advanced Chart

1.170

-0.04(-3.306%)1D

Overview
Forecast
Valuation
Earnings

LCTX Relative Valuation

LCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LCTX is overvalued; if below, it's undervalued.

Historical Valuation

Lineage Cell Therapeutics Inc (LCTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.46 is considered Undervalued compared with the five-year average of -9.15. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 2.03 to 2.95 according to relative valuation methord. Compared to the current price of 1.17 USD , Lineage Cell Therapeutics Inc is Undervalued By 42.39%.

Relative Value

Fair Zone

2.03-2.95

Current Price：1.17

42.39%

Undervalued

-15.02

Trailing

Forward

-8.96

EV/EBITDA

Lineage Cell Therapeutics Inc. (LCTX) has a current EV/EBITDA of -8.96. The 5-year average EV/EBITDA is -13.40. The thresholds are as follows: Strongly Undervalued below -65.61, Undervalued between -65.61 and -39.51, Fairly Valued between 12.71 and -39.51, Overvalued between 12.71 and 38.81, and Strongly Overvalued above 38.81. The current Forward EV/EBITDA of -8.96 falls within the Historic Trend Line -Fairly Valued range.

-9.79

EV/EBIT

Lineage Cell Therapeutics Inc. (LCTX) has a current EV/EBIT of -9.79. The 5-year average EV/EBIT is -7.08. The thresholds are as follows: Strongly Undervalued below -13.10, Undervalued between -13.10 and -10.09, Fairly Valued between -4.07 and -10.09, Overvalued between -4.07 and -1.06, and Strongly Overvalued above -1.06. The current Forward EV/EBIT of -9.79 falls within the Historic Trend Line -Fairly Valued range.

14.46

Lineage Cell Therapeutics Inc. (LCTX) has a current PS of 14.46. The 5-year average PS is 43.78. The thresholds are as follows: Strongly Undervalued below -56.20, Undervalued between -56.20 and -6.21, Fairly Valued between 93.78 and -6.21, Overvalued between 93.78 and 143.77, and Strongly Overvalued above 143.77. The current Forward PS of 14.46 falls within the Historic Trend Line -Fairly Valued range.

-10.19

P/OCF

Lineage Cell Therapeutics Inc. (LCTX) has a current P/OCF of -10.19. The 5-year average P/OCF is -3.11. The thresholds are as follows: Strongly Undervalued below -58.03, Undervalued between -58.03 and -30.57, Fairly Valued between 24.34 and -30.57, Overvalued between 24.34 and 51.80, and Strongly Overvalued above 51.80. The current Forward P/OCF of -10.19 falls within the Historic Trend Line -Fairly Valued range.

-14.68

P/FCF

Lineage Cell Therapeutics Inc. (LCTX) has a current P/FCF of -14.68. The 5-year average P/FCF is -23.43. The thresholds are as follows: Strongly Undervalued below -167.15, Undervalued between -167.15 and -95.29, Fairly Valued between 48.43 and -95.29, Overvalued between 48.43 and 120.29, and Strongly Overvalued above 120.29. The current Forward P/FCF of -14.68 falls within the Historic Trend Line -Fairly Valued range.

Lineage Cell Therapeutics Inc (LCTX) has a current Price-to-Book (P/B) ratio of 5.52. Compared to its 3-year average P/B ratio of 2.79 , the current P/B ratio is approximately 97.61% higher. Relative to its 5-year average P/B ratio of 2.90, the current P/B ratio is about 90.37% higher. Lineage Cell Therapeutics Inc (LCTX) has a Forward Free Cash Flow (FCF) yield of approximately -8.66%. Compared to its 3-year average FCF yield of -11.59%, the current FCF yield is approximately -25.27% lower. Relative to its 5-year average FCF yield of -9.07% , the current FCF yield is about -4.47% lower.

5.52

P/B

Median3y

2.79

Median5y

2.90

-8.66

FCF Yield

Median3y

-11.59

Median5y

-9.07

Competitors Valuation Multiple

The average P/S ratio for LCTX's competitors is 79.32, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX) exhibits a P/S ratio of 14.46, which is -81.77% above the industry average. Given its robust revenue growth of 96.38%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LCTX.A

Lineage Cell Therapeutics Inc

Eupraxia Pharmaceuticals Inc

Loss

192.74M

MREO.O

Mereo BioPharma Group PLC

8.78

272.06M

RNAC.O

Cartesian Therapeutics Inc

Galectin Therapeutics Inc

Loss

274.18M

Performance Decomposition

Market capitalization of LCTX increased by 28.57% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -410.01 to -1.10K.

The secondary factor is the Revenue Growth, contributed 96.38%to the performance.

Overall, the performance of LCTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

96.38%

1.41M → 2.77M

Revenue Growth

167.84%

-410.01 → -1.10K

Margin Expansion

-235.65%

4.66 → -6.32

P/E Change

28.57%